407 related articles for article (PubMed ID: 19563607)
1. Neutrophils: key mediators of tumour angiogenesis.
Tazzyman S; Lewis CE; Murdoch C
Int J Exp Pathol; 2009 Jun; 90(3):222-31. PubMed ID: 19563607
[TBL] [Abstract][Full Text] [Related]
2. Neutrophil-mediated tumour angiogenesis: subversion of immune responses to promote tumour growth.
Tazzyman S; Niaz H; Murdoch C
Semin Cancer Biol; 2013 Jun; 23(3):149-58. PubMed ID: 23410638
[TBL] [Abstract][Full Text] [Related]
3. The role of myeloid cells in the promotion of tumour angiogenesis.
Murdoch C; Muthana M; Coffelt SB; Lewis CE
Nat Rev Cancer; 2008 Aug; 8(8):618-31. PubMed ID: 18633355
[TBL] [Abstract][Full Text] [Related]
4. Mast cell contribution to angiogenesis related to tumour progression.
Ribatti D; Crivellato E; Roccaro AM; Ria R; Vacca A
Clin Exp Allergy; 2004 Nov; 34(11):1660-4. PubMed ID: 15544587
[TBL] [Abstract][Full Text] [Related]
5. Targeting both tumour-associated CXCR2
Nywening TM; Belt BA; Cullinan DR; Panni RZ; Han BJ; Sanford DE; Jacobs RC; Ye J; Patel AA; Gillanders WE; Fields RC; DeNardo DG; Hawkins WG; Goedegebuure P; Linehan DC
Gut; 2018 Jun; 67(6):1112-1123. PubMed ID: 29196437
[TBL] [Abstract][Full Text] [Related]
6. The vascular targeting agent combretastatin A-4-phosphate induces neutrophil recruitment to endothelial cells in vitro.
Brooks AC; Kanthou C; Cook IH; Tozer GM; Barber PR; Vojnovic B; Nash GB; Parkins CS
Anticancer Res; 2003; 23(4):3199-206. PubMed ID: 12926054
[TBL] [Abstract][Full Text] [Related]
7. Lysyl oxidase-like-2 promotes tumour angiogenesis and is a potential therapeutic target in angiogenic tumours.
Zaffryar-Eilot S; Marshall D; Voloshin T; Bar-Zion A; Spangler R; Kessler O; Ghermazien H; Brekhman V; Suss-Toby E; Adam D; Shaked Y; Smith V; Neufeld G
Carcinogenesis; 2013 Oct; 34(10):2370-9. PubMed ID: 23828904
[TBL] [Abstract][Full Text] [Related]
8. Neutrophil infiltration into human gliomas.
Fossati G; Ricevuti G; Edwards SW; Walker C; Dalton A; Rossi ML
Acta Neuropathol; 1999 Oct; 98(4):349-54. PubMed ID: 10502039
[TBL] [Abstract][Full Text] [Related]
9. A reinforced random walk model of tumour angiogenesis and anti-angiogenic strategies.
Plank MJ; Sleeman BD
Math Med Biol; 2003 Jun; 20(2):135-81. PubMed ID: 14636027
[TBL] [Abstract][Full Text] [Related]
10. Tumour cell apoptosis modulates the colorectal cancer immune microenvironment via interleukin-8-dependent neutrophil recruitment.
Schimek V; Strasser K; Beer A; Göber S; Walterskirchen N; Brostjan C; Müller C; Bachleitner-Hofmann T; Bergmann M; Dolznig H; Oehler R
Cell Death Dis; 2022 Feb; 13(2):113. PubMed ID: 35121727
[TBL] [Abstract][Full Text] [Related]
11. [Tumor-associated macrophages in the prospect of development of targeted cancer therapy].
Skivka LM; Horbyk HV; Fedorchuk OH; Pozur VV
Tsitol Genet; 2009; 43(4):71-82. PubMed ID: 19938649
[TBL] [Abstract][Full Text] [Related]
12. The rationale and future potential of angiogenesis inhibitors in neoplasia.
Gasparini G
Drugs; 1999 Jul; 58(1):17-38. PubMed ID: 10439927
[TBL] [Abstract][Full Text] [Related]
13. Mast cells, angiogenesis, and tumour growth.
Ribatti D; Crivellato E
Biochim Biophys Acta; 2012 Jan; 1822(1):2-8. PubMed ID: 21130163
[TBL] [Abstract][Full Text] [Related]
14. Tumour angiogenesis: its mechanism and therapeutic implications in malignant gliomas.
Wong ML; Prawira A; Kaye AH; Hovens CM
J Clin Neurosci; 2009 Sep; 16(9):1119-30. PubMed ID: 19556134
[TBL] [Abstract][Full Text] [Related]
15. Antiangiogenic effects of marine sponge derived compounds on cancer.
Senthilkumar K; Venkatesan J; Manivasagan P; Kim SK
Environ Toxicol Pharmacol; 2013 Nov; 36(3):1097-108. PubMed ID: 24148290
[TBL] [Abstract][Full Text] [Related]
16. Tumour-infiltrating neutrophils counteract anti-VEGF therapy in metastatic colorectal cancer.
Schiffmann LM; Fritsch M; Gebauer F; Günther SD; Stair NR; Seeger JM; Thangarajah F; Dieplinger G; Bludau M; Alakus H; Göbel H; Quaas A; Zander T; Hilberg F; Bruns CJ; Kashkar H; Coutelle O
Br J Cancer; 2019 Jan; 120(1):69-78. PubMed ID: 30377339
[TBL] [Abstract][Full Text] [Related]
17. Role of the tumor stroma in resistance to anti-angiogenic therapy.
Huijbers EJ; van Beijnum JR; Thijssen VL; Sabrkhany S; Nowak-Sliwinska P; Griffioen AW
Drug Resist Updat; 2016 Mar; 25():26-37. PubMed ID: 27155374
[TBL] [Abstract][Full Text] [Related]
18. Tumour angiogenesis, anti-angiogenic therapy and chemotherapeutic resistance.
Mander KA; Finnie JW
Aust Vet J; 2018 Oct; 96(10):371-378. PubMed ID: 30255577
[TBL] [Abstract][Full Text] [Related]
19. Use of angiogenesis inhibitors in tumour treatment.
Fayette J; Soria JC; Armand JP
Eur J Cancer; 2005 May; 41(8):1109-16. PubMed ID: 15911233
[TBL] [Abstract][Full Text] [Related]
20. Novel anti-angiogenic therapies for malignant gliomas.
Norden AD; Drappatz J; Wen PY
Lancet Neurol; 2008 Dec; 7(12):1152-60. PubMed ID: 19007739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
